191 related articles for article (PubMed ID: 8388347)
1. Heparin/low molecular weight heparin and tissue factor pathway inhibitor.
Abildgaard U
Haemostasis; 1993 Mar; 23 Suppl 1():103-6. PubMed ID: 8388347
[TBL] [Abstract][Full Text] [Related]
2. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations.
Ostergaard P; Nordfang O; Petersen LC; Valentin S; Kristensen H
Haemostasis; 1993 Mar; 23 Suppl 1():107-11. PubMed ID: 8388348
[TBL] [Abstract][Full Text] [Related]
3. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
4. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behçet's disease and systemic lupus erythematosus: effect on the prethrombotic state.
Ertenli I; Kiraz S; Celik IC; Haznedaroglu C; Erman M; Calgüneri M; Kirazli S
Ann Rheum Dis; 2001 Dec; 60(12):1149-51. PubMed ID: 11709459
[TBL] [Abstract][Full Text] [Related]
5. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
[TBL] [Abstract][Full Text] [Related]
6. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
Kaiser B; Hoppensteadt DA; Jeske W; Wun TC; Fareed J
Thromb Res; 1994 Sep; 75(6):609-16. PubMed ID: 7831680
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A
Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
[TBL] [Abstract][Full Text] [Related]
9. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
Sandset PM; Bendz B; Hansen JB
Haemostasis; 2000; 30 Suppl 2():48-56. PubMed ID: 11251341
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
Bara L; Bloch MF; Zitoun D; Samama M; Collignon F; Frydman A; Uzan A; Bouthier J
Thromb Res; 1993 Mar; 69(5):443-52. PubMed ID: 8388583
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays.
Valentin S; Ostergaard P; Kristensen H; Nordfang O
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):629-35. PubMed ID: 1664252
[TBL] [Abstract][Full Text] [Related]
12. Tissue factor pathway inhibitor (TFPI)--an update.
Sandset PM
Haemostasis; 1996 Oct; 26 Suppl 4():154-65. PubMed ID: 8979119
[TBL] [Abstract][Full Text] [Related]
13. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
[TBL] [Abstract][Full Text] [Related]
14. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
Hamamoto T; Kisiel W
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin.
Mousa SA
Int Angiol; 2006 Mar; 25(1):10-3. PubMed ID: 16520718
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
17. Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits.
Zitoun D; Bara L; Bloch MF; Samama MM
Thromb Res; 1994 Sep; 75(5):577-80. PubMed ID: 7992258
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
Mousa SA; Mohamed S
Thromb Haemost; 2004 Sep; 92(3):627-33. PubMed ID: 15351861
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
Li Y; Rodriquez M; Spencer FA; Becker RC
J Thromb Thrombolysis; 2002 Oct; 14(2):123-9. PubMed ID: 12714831
[TBL] [Abstract][Full Text] [Related]
20. The role of tissue factor pathway inhibitor in tumor growth and metastasis.
Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL
Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
